Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals develops and commercializes oral small-molecule therapies for rare diseases, with a focus on the kallikrein-kinin system. Its FDA-approved product EKTERLY (sebetralstat) is an oral plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema, and company updates often center on launch activity, product revenue, and use of oral on-demand therapy in HAE.
KalVista news also covers clinical and scientific updates for sebetralstat, including pediatric HAE work through the KONFIDENT-KID trial, medical-conference presentations, financial results, inducement equity grants, governance matters, capital-structure disclosures, and material agreements.
KalVista Pharmaceuticals announced new data on sebetralstat, published in the Journal of Medicinal Chemistry and Xenobiotica. The research highlights its effectiveness as an on-demand treatment for hereditary angioedema (HAE), showcasing high selectivity against human serine proteases and rapid absorption characteristics, essential for patient needs. Sebetralstat has progressed to Phase 3 KONFIDENT trials, indicating significant advancement towards clinical application. CEO Andrew Crockett expressed optimism about sebetralstat's promise for HAE treatment.
KalVista Pharmaceuticals has announced a significant leadership change, appointing Brian J.G. Pereira, M.D. as the new Chairman of the Board, effective immediately. He replaces Martin Edwards, M.D., who is retiring in a planned transition. Dr. Pereira brings extensive experience in late-stage drug development, crucial for advancing KalVista's lead candidate, sebetralstat, which targets hereditary angioedema (HAE) attacks. The company is currently enrolling participants in the Phase 3 KONFIDENT clinical trial.
KalVista Pharmaceuticals presented new data on patient perspectives regarding treatment outcome measures from the phase 3 KONFIDENT trial of sebetralstat at the 2022 HAEi Global Leadership Workshop. The research showed a strong patient preference for using the Patient Global Impression of Change (PGI-C) scale as a clinical endpoint, with over 70% favoring it over other scales. Additionally, findings highlighted the significant mental health impacts of hereditary angioedema (HAE) on patients, with many missing important life events due to anxiety linked to their condition.
KalVista Pharmaceuticals (NASDAQ: KALV) is under investigation by Holzer & Holzer, LLC for potential violations of federal securities laws. This follows the termination of its KOMPLETE phase 2 clinical trial for KVD824 on October 4, 2022, due to elevated liver enzymes observed in all treatment groups. This announcement resulted in a drop in the company's stock price. Investors who incurred losses on their KalVista stock are encouraged to contact Holzer & Holzer for legal advice regarding their rights.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the granting of inducement stock options to four newly-hired employees, totaling 18,000 shares. These options, priced at $14.24 per share, correspond to the closing stock price on October 3, 2022. They vest quarterly over four years, contingent upon continued employment. KalVista specializes in developing oral small molecule protease inhibitors targeting unmet medical needs, with ongoing clinical trials for treatments in hereditary angioedema and diabetic macular edema.
KalVista Pharmaceuticals (NASDAQ: KALV) has terminated the KOMPLETE Phase 2 clinical trial for KVD824 due to observed elevations in liver enzymes among participants. The company confirmed that these findings do not impact the safety profile of Sebetralstat or the ongoing Phase 3 KONFIDENT trial.
KalVista will focus on advancing Sebetralstat towards a planned NDA filing in 2024 and will prioritize its oral Factor XIIa program for hereditary angioedema (HAE) prophylaxis, aiming for a once-daily therapy.
KalVista Pharmaceuticals (NASDAQ: KALV) has announced the acceptance of multiple abstracts for presentation at the HAE International Global Leadership Workshop in Frankfurt, Germany, from October 6-9, 2022. The presentations focus on patient perspectives regarding optimal treatment outcomes for Hereditary Angioedema (HAE), emphasizing its effects on mental health and quality of life. Notable presentations include a poster on optimal outcome measures and a session on the global impact of HAE attacks. Both presentations are scheduled for October 7 from 2:30-3:30 CET.
KalVista Pharmaceuticals (KALV) announced a significant milestone as its KVD824 Phase 2 clinical trial surpassed 50% enrollment, marking a key step in developing a potential oral prophylactic treatment for hereditary angioedema (HAE). The company has also initiated the KONFIDENT-S open label extension study for sebetralstat, aimed at providing detailed safety data and exploring its usage in adolescents. However, KalVista reported no revenue for the first fiscal quarter, with a net loss of $23 million, reflecting increased R&D and G&A expenses. Cash holdings decreased to $142.1 million.
KalVista Pharmaceuticals recently granted inducement stock options to five new employees, totaling 18,000 shares at an exercise price of $16.83 per share, aligning with the company's stock price on the grant date of September 1, 2022. The options will vest over four years, starting with one-fourth on the anniversary of the commencement date. This initiative adheres to Nasdaq Listing Rule 5635(c)(4), reflecting KalVista's focus on growth and talent acquisition in the pharmaceutical sector.
KalVista Pharmaceuticals (KALV) announced the initiation of its KONFIDENT-S open-label extension study, providing an additional two years of treatment with sebetralstat for hereditary angioedema (HAE) patients. This trial is designed to assess long-term safety and efficacy, with a subtrial including adolescents aged 12-17. Data collected will support a planned FDA NDA filing in 2024, following the ongoing Phase 3 KONFIDENT trial expected to conclude in late 2023. The company aims to position sebetralstat as the first oral, on-demand treatment for HAE.